CN102440957A - Terlipressin acetate nasal cavity spray and preparation method thereof - Google Patents
Terlipressin acetate nasal cavity spray and preparation method thereof Download PDFInfo
- Publication number
- CN102440957A CN102440957A CN2011104276360A CN201110427636A CN102440957A CN 102440957 A CN102440957 A CN 102440957A CN 2011104276360 A CN2011104276360 A CN 2011104276360A CN 201110427636 A CN201110427636 A CN 201110427636A CN 102440957 A CN102440957 A CN 102440957A
- Authority
- CN
- China
- Prior art keywords
- terlipressin
- nasal mist
- acetic acid
- preferred
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a terlipressin acetate nasal cavity spray and a preparation method thereof. The spray is composed by terlipressin acetate, absorption enhancer, osmotic pressure regulator, preservative and pH regulator. The preparation method of the spray mainly comprises raw material preparing, dissolving, bottle washing, filling, packing and the like. The spray has the main functions of contracting smooth muscles of visceral vessels and reducing blood flow volume of the viscera, accordingly, the portal vein blood flow and portal vein pressure are reduced, and meanwhile, the spray can be used for the smooth muscles of the esophagus and the uterus. The spray is convenient to dose, has high bioavailability, and is beneficial to patients to accept.
Description
Technical field:
The present invention relates to formulation art, specifically is a kind of nasal mist of acetic acid terlipressin and preparation method thereof.
Background technology:
Terlipressin is an artificial synthetic polypeptide; Being the analog of lobus posterior hypophyseos secreting hormone, is a kind of long-acting vasopressin of novel synthetic, and it is a kind of prodrug; Non-activity own; In vivo through the amino peptidase effect, slough 3 glycyl residues of its N-terminal after, slowly release activated Schweine-Vasopressin.It is to shrink the visceral vessel smooth muscle that terlipressin mainly acts on, and reduces SBF, thereby reduces portal venous flow, reduction portal pressure, also can act on smooth muscle such as esophagus and uterus simultaneously.This medicine at present clinically application forms be mainly injection, the injection use needs particular environment, generally is confined to hospital, uses inconvenience, and patient will bear certain misery and bears with high economic.The nasal mist convenient drug administration that the present invention relates to, particularly along with the raising of nasal spray device investigative technique, the nasal mist utilization ratio of drug is high, and the patient is easier to accept.
Summary of the invention:
The objective of the invention is to prepare a kind of is the nasal mist of active component with the acetic acid terlipressin, has convenient drug administration, receives medicine even, advantages such as bioavailability height.
The present invention has prepared a kind of nasal mist that contains acetic acid terlipressin medicine, and it comprises acetic acid terlipressin, absorption enhancer, osmotic pressure regulator, antiseptic, PH regulator.
The present invention has prepared a kind of nasal mist that contains acetic acid terlipressin medicine, and its absorption enhancer is selected from disodiumedetate, sodium deoxycholate, beta-schardinger dextrin-, hydroxypropyl emthylcellulose, cyclodextrin derivative, azone, chitosan etc.; Its antiseptic is selected from chlorobutanol, benzoic acid, sorbic acid, methyl parahydroxybenzoate, benzalkonium chloride etc.; Its osmotic pressure regulator is selected from sodium chloride, potassium chloride, mannitol, glucose, phosphate, citrate, phosphate etc.; The PH regulator is selected from hydrochloric acid, acetic acid, phosphoric acid, the acid of structure rafter or sodium hydroxide etc.
Through a large amount of optimization experiment, the present invention has found that most preferably prescription is formed.Wherein, the preferred disodiumedetate of its absorption enhancer, the preferred sodium chloride of osmotic pressure regulator, the preferred chlorobutanol of antiseptic, the preferred acetic acid of PH regulator, pH is 5.0-6.5 most preferably.
In addition, the present invention also provides preparation to contain the method for the nasal mist of acetic acid terlipressin medicine.Its technology is following:
(1) absorption enhancer, osmotic pressure regulator, antiseptic is soluble in water, fully dissolving;
(2) add terlipressin or its pharmaceutically acceptable salt in the aqueous solution that in step (1), obtains, and it is fully dissolved;
(3) add the pH regulator agent in the aqueous solution that in step (2), obtains, be adjusted to required pH value;
(4) solution of purified water standardize solution step (3) acquisition, 0.22 μ m filtering with microporous membrane;
(5) fill to sterilized spray bottle after the passed examination, and add the bottle cap that has the dosing pump of spraying; The labeling packing.
The specific embodiment:
In conjunction with embodiment embodiment of the present invention are described in detail, but it will be understood to those of skill in the art that the following example only is used to explain the present invention, and should not be regarded as limiting scope of the present invention.
Embodiment 1:
Embodiment 1 acetic acid terlipressin nasal spray agent prescription is: 1.0mg/ml acetic acid terlipressin, and the 0.1%w/v disodiumedetate, 0.80%w/v sodium chloride, the 0.30%w/v chlorobutanol, it is 5.5 that acetic acid is regulated pH.
Its preparation process is following: precision takes by weighing the 100mg disodiumedetate; 800mg sodium chloride, 300mg chlorobutanol add purified water and fully dissolve in the 1000ml beaker; Add 1000mg acetic acid terlipressin then; It is fully dissolved, and adding an amount of acetic acid adjusting pH value is 5.5, the purified water standardize solution.0.22 μ m filtering with microporous membrane, fill to sterilized spray bottle after the passed examination, and add the bottle cap that has the dosing pump of spraying; The labeling packing gets acetic acid terlipressin nasal mist.
Make by present embodiment and to contain 1.0mg/ml acetic acid terlipressin nasal mist 10 spray and injection terlipressin 10 pins,, its pharmacokinetics and bioavailability are investigated through zoopery.
With 8 grow up, healthy beasle dog is divided into two groups, 4 every group immediately.Give above-mentioned two groups of beasle dogs respectively with the nasal mist and the injection terlipressin of above-mentioned acetic acid terlipressin, measure main pharmacokinetic parameter, comprise medicine removing half-life (t
1/2), clearance rate (CL), apparent volume of distribution (Vd), the result is as shown in table 1 for its meansigma methods:
Table 1 acetic acid terlipressin nasal mist and injection pharmacokinetic parameter
Can find out that through table 1 the acetic acid terlipressin nasal mist and the injection terlipressin of the present invention's preparation compare, the pharmacokinetics index is more excellent; And it is easy to use; No pain, patient's acceptance level is high, can substitute this conventional dosage forms of injection terlipressin fully.
Simultaneously, the present invention also is employed in body toad palate modelling, the acetic acid terlipressin nasal mist of present embodiment preparation is investigated the influence of nose fibre swing time, and with the normal saline matched group, assessed its stimulation to nasal membrane.The result shows that acetic acid terlipressin nasal mist is contrast with the normal saline, and the nasal mucosa fibre swing time is not had influence.
Moreover; The present invention also utilizes rat experiment; Acetic acid terlipressin nasal mist nasal mucosa form influence to the present embodiment preparation is investigated; With the normal saline is matched group, and the result shows that the acetic acid terlipressin nasal mist of present embodiment preparation is non-stimulated to nasal mucosa morphogenetic stimulus rank.
Embodiment 2:
Embodiment 2 acetic acid terlipressin nasal spray agent prescriptions are: 1.0mg/ml acetic acid terlipressin, and the 0.5%w/v sodium deoxycholate, the 1.0%w/v glucose, the 0.40%w/v chlorobutanol, it is 5.5 that acetic acid is regulated pH, its preparation technology is following:
Its preparation process is following: precision takes by weighing the 500mg sodium deoxycholate; 1000mg glucose, 400mg chlorobutanol add purified water and fully dissolve in the 1000ml beaker; Add 1000mg acetic acid terlipressin then; It is fully dissolved, and adding an amount of acetic acid adjusting pH value is 5.5, the purified water standardize solution.0.22 μ m filtering with microporous membrane, fill to sterilized spray bottle after the passed examination, and add the bottle cap that has the dosing pump of spraying; The labeling packing gets acetic acid terlipressin nasal mist.
Make by present embodiment and to contain 1.0mg/ml acetic acid terlipressin nasal mist 10 spray and injection terlipressin 10 pins,, its pharmacokinetics and bioavailability are investigated through zoopery.
With 8 grow up, healthy beasle dog is divided into two groups, 4 every group immediately.Give above-mentioned two groups of beasle dogs respectively with the nasal mist and the injection terlipressin of above-mentioned acetic acid terlipressin, measure main pharmacokinetic parameter, comprise medicine removing half-life (t
1/2), clearance rate (CL), apparent volume of distribution (Vd), the result is as shown in table 2 for its meansigma methods:
Table 2 acetic acid terlipressin nasal mist and injection pharmacokinetic parameter
Can find out that through table 2 the acetic acid terlipressin nasal mist and the injection terlipressin of the present invention's preparation compare, the pharmacokinetics index is poor slightly; But it is easy to use; No pain, patient's acceptance level is high, can substitute this conventional dosage forms of injection terlipressin.
Simultaneously, the present invention also is employed in body toad palate modelling, the acetic acid terlipressin nasal mist of present embodiment preparation is investigated the influence of nose fibre swing time, and with the normal saline matched group, assessed its stimulation to nasal membrane.The result shows that acetic acid terlipressin nasal mist is contrast with the normal saline, and is slightly influential to the nasal mucosa fibre swing time.
Moreover; The present invention also utilizes rat experiment; Acetic acid terlipressin nasal mist nasal mucosa form influence to the present embodiment preparation is investigated; With the normal saline is matched group, and the result shows that the acetic acid terlipressin nasal mist of present embodiment preparation is non-stimulated to nasal mucosa morphogenetic stimulus rank.
Embodiment 3:
Embodiment 3 acetic acid terlipressin nasal spray agent prescriptions are: 1.5mg/ml acetic acid terlipressin, 0.5%w/v disodiumedetate, 0.5%w/v chitosan; 1.0%w/v sodium chloride; The 0.30%w/v chlorobutanol, it is 6.5 that acetic acid is regulated pH, its preparation technology is following:
Its preparation process is following: precision takes by weighing the 500mg disodiumedetate, 500mg chitosan, 1000mg sodium chloride; The 300mg chlorobutanol is in the 1000ml beaker; Add purified water and fully dissolve, add 1500mg acetic acid terlipressin then, it is fully dissolved; Adding an amount of acetic acid adjusting pH value is 6.5, the purified water standardize solution.0.22 μ m filtering with microporous membrane, fill to sterilized spray bottle after the passed examination, and add the bottle cap that has the dosing pump of spraying; The labeling packing gets acetic acid terlipressin nasal mist.
Make by present embodiment and to contain 1.5mg/ml acetic acid terlipressin nasal mist 10 spray and injection terlipressin 10 pins,, its pharmacokinetics and bioavailability are investigated through zoopery.
With 8 grow up, healthy beasle dog is divided into two groups, 4 every group immediately.Give above-mentioned two groups of beasle dogs respectively with the nasal mist and the injection terlipressin of above-mentioned acetic acid terlipressin, measure main pharmacokinetic parameter, comprise medicine removing half-life (t
1/2), clearance rate (CL), apparent volume of distribution (Vd), the result is as shown in table 3 for its meansigma methods:
Table 3 acetic acid terlipressin nasal mist and injection pharmacokinetic parameter
Can find out that through table 3 the acetic acid terlipressin nasal mist and the injection terlipressin of the present invention's preparation compare, the pharmacokinetics index is more excellent; And it is easy to use; No pain, patient's acceptance level is high, can substitute this conventional dosage forms of injection terlipressin fully.
Simultaneously, the present invention also is employed in body toad palate modelling, the acetic acid terlipressin nasal mist of present embodiment preparation is investigated the influence of nose fibre swing time, and with the normal saline matched group, assessed its stimulation to nasal membrane.The result shows that acetic acid terlipressin nasal mist is contrast with the normal saline, and the nasal mucosa fibre swing time is not had influence.
Moreover; The present invention also utilizes rat experiment; Acetic acid terlipressin nasal mist nasal mucosa form influence to the present embodiment preparation is investigated; With the normal saline is matched group, and the result shows that the acetic acid terlipressin nasal mist of present embodiment preparation is a minimal irritation to nasal mucosa morphogenetic stimulus rank.
Claims (10)
1. terlipressin nasal mist; It is characterized in that: comprise terlipressin or its pharmaceutically acceptable salt 0.1-100mg/ml; Absorption enhancer 0.01-5.0%w/v; Osmotic pressure regulator 0.01-5.0%w/v, antiseptic 0.01-2.0%w/v and pH regulator agent, its pH scope is 4.0-6.5.
2. terlipressin nasal mist according to claim 1; Wherein said terlipressin pharmaceutically acceptable salt is an acid-addition salts; Can be hydrochlorate, sulfate, acetate, lactate, citrate, structure same regimen acid salt, phosphate or its mixture; Be preferably the acetic acid terlipressin, content is preferably 0.1-50mg/ml.
3. according to the said terlipressin nasal mist of claim 1, its absorption enhancer is selected from disodiumedetate, sodium deoxycholate, beta-schardinger dextrin-, hydroxypropyl emthylcellulose, cyclodextrin derivative, azone, chitosan etc.
4. according to the said terlipressin nasal mist of claim 3, the preferred disodiumedetate of its absorption enhancer, the preferred 0.01-2.0%w/v of content.
5. according to the said terlipressin nasal mist of claim 1, its osmotic pressure regulator is selected from sodium chloride, potassium chloride, mannitol, glucose, phosphate, citrate, phosphate etc.
6. according to the said terlipressin nasal mist of claim 5, the preferred sodium chloride of its osmotic pressure regulator, the preferred 0.1-1.5%w/v of content.
7. according to the said terlipressin nasal mist of claim 1, its antiseptic is selected from chlorobutanol, benzoic acid, sorbic acid, methyl parahydroxybenzoate, benzalkonium chloride etc.
8. according to the said terlipressin nasal mist of claim 7, the preferred chlorobutanol of its antiseptic, the preferred 0.01-0.5%w/v of content.
9. the said terlipressin nasal mist of claim 1, its pH regulator agent is selected from hydrochloric acid, acetic acid, phosphoric acid, the acid of structure rafter or sodium hydroxide etc., preferred acetic acid, the preferred 5.0-6.5 of pH value.
10. the said preparation of claim 1, its preparation technology is following:
(1) absorption enhancer, osmotic pressure regulator, antiseptic is soluble in water, fully dissolving;
(2) add terlipressin or its pharmaceutically acceptable salt in the aqueous solution that in step (1), obtains, and it is fully dissolved;
(3) add the pH regulator agent in the aqueous solution that in step (2), obtains, be adjusted to required pH value;
(4) solution of purified water standardize solution step (3) acquisition, 0.22 μ m filtering with microporous membrane;
(5) fill to sterilized spray bottle after the passed examination, and add the bottle cap that has the dosing pump of spraying; The labeling packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104276360A CN102440957B (en) | 2011-12-16 | 2011-12-16 | Terlipressin acetate nasal cavity spray and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104276360A CN102440957B (en) | 2011-12-16 | 2011-12-16 | Terlipressin acetate nasal cavity spray and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102440957A true CN102440957A (en) | 2012-05-09 |
| CN102440957B CN102440957B (en) | 2013-09-25 |
Family
ID=46004219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104276360A Active CN102440957B (en) | 2011-12-16 | 2011-12-16 | Terlipressin acetate nasal cavity spray and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102440957B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019239386A1 (en) * | 2018-06-15 | 2019-12-19 | Ferring B.V. | Terlipressin compositions and uses thereof |
| WO2020237170A1 (en) * | 2019-05-22 | 2020-11-26 | Biovie Inc. | Formulations of terlipressin |
| CN113453661A (en) * | 2018-12-21 | 2021-09-28 | 艾瑞克有限公司 | New composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126440A (en) * | 1993-06-29 | 1996-07-10 | 凡林有限公司 | Stabilized pharmaceutical peptide compositions |
| CN1126439A (en) * | 1993-06-29 | 1996-07-10 | 凡林有限公司 | Compositions for nasal administration of desmopressin |
-
2011
- 2011-12-16 CN CN2011104276360A patent/CN102440957B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126440A (en) * | 1993-06-29 | 1996-07-10 | 凡林有限公司 | Stabilized pharmaceutical peptide compositions |
| CN1126439A (en) * | 1993-06-29 | 1996-07-10 | 凡林有限公司 | Compositions for nasal administration of desmopressin |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019239386A1 (en) * | 2018-06-15 | 2019-12-19 | Ferring B.V. | Terlipressin compositions and uses thereof |
| CN112969449A (en) * | 2018-06-15 | 2021-06-15 | 费灵有限公司 | Terlipressin composition and application thereof |
| US11931398B2 (en) | 2018-06-15 | 2024-03-19 | Ferring B.V. | Terlipressin compositions and uses thereof |
| CN113453661A (en) * | 2018-12-21 | 2021-09-28 | 艾瑞克有限公司 | New composition |
| WO2020237170A1 (en) * | 2019-05-22 | 2020-11-26 | Biovie Inc. | Formulations of terlipressin |
| EP3972628A4 (en) * | 2019-05-22 | 2023-01-18 | Biovie Inc. | Formulations of terlipressin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102440957B (en) | 2013-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008727B (en) | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation | |
| DK2574167T3 (en) | LIQUID NOSE SPRAY CONTAINING low-dose naltrexone | |
| WO2013177565A1 (en) | Insulin-pramlintide compositions and methods for making and using them | |
| JP2003506416A (en) | Moxifloxacin / sodium chloride preparation | |
| JP5993442B2 (en) | Pharmaceutical composition | |
| CN101214235A (en) | Ibuprofen amino acid salt injection and preparation thereof | |
| CN102440957B (en) | Terlipressin acetate nasal cavity spray and preparation method thereof | |
| MXPA06009094A (en) | Controlled release formulations. | |
| CN102670489A (en) | Ropivacaine hydrochloride sodium chloride injection and preparation method thereof | |
| TW201729830A (en) | Pharmaceutical composition intended to be administred to nasal mucosa | |
| TW201440783A (en) | Pharmaceutical composition comprising micafungin or the salts thereof | |
| CN102885766B (en) | Dexketoprofen injection and preparation method thereof | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| CN102274194B (en) | Pharmaceutical composition containing tropisetron compound and preparation method thereof | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN102380088A (en) | Prescription and preparation method of thymopeptide-5 injection | |
| EP3236956A1 (en) | Combination of remifentanil and propofol | |
| CN102716107B (en) | water-soluble ibuprofen pharmaceutical composition | |
| CN103989685A (en) | Preparation method of compound lamotrigine subcutaneous implantable controlled-release glue rod | |
| CN101780061A (en) | Nasal spray | |
| CN108992394A (en) | A kind of preparation method of pseudoephedrine hydrochloride slow release preparation | |
| CN115919858A (en) | Analgesic pharmaceutical composition, preparation method and application thereof | |
| TW201440782A (en) | Pharmaceutical composition of micafungin or the salts thereof | |
| CN115518035A (en) | Ketorolac liquid composition, preparation method and application thereof | |
| WO2021158957A1 (en) | Drug products for intranasal administration and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 518057 Nanshan District, Guangdong Province, a high tech in the middle of the road No. ten Shenzhen biological incubation base, building 412, room 2, No. Applicant after: Shenzhen City Jianyuan Pharmaceutical Technology Co., Ltd. Address before: 518000, overseas student Pioneer Building, 29 South Ring Road, Nanshan hi tech Zone, Guangdong, Shenzhen 1702 Applicant before: Shenzhen City Jianyuan Pharmaceutical Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120509 Assignee: Nanjing Xingyin Pharmaceutical Group Co.,Ltd. Assignor: Shenzhen City Jianyuan Pharmaceutical Technology Co., Ltd. Contract record no.: 2015440020183 Denomination of invention: Terlipressin acetate nasal cavity spray and preparation method thereof Granted publication date: 20130925 License type: Exclusive License Record date: 20150519 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161209 Address after: Zi street Jinhui road Shenzhen 518118 Guangdong province Pingshan pit No. 14 Shenzhen Biomedical Innovation Industrial Park Building No. 7 Patentee after: Shenzhen Jianxiang Biological Pharmaceutical Co Ltd Address before: 518057 Nanshan District, Guangdong Province, a high tech in the middle of the road No. ten Shenzhen biological incubation base, building 412, room 2, No. Patentee before: Shenzhen City Jianyuan Pharmaceutical Technology Co., Ltd. |